Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 489 - #Psychedelic Spotlight-(CSE: $SPOR.C) (OTC: $TRMNF) (NEO: MMED) (OTCQB: $MMEDF)
Today's podcast sponsored by Cannabis Suisse Corp.
(OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in
Switzerland
Delta, Kelowna, BC, October 30, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/103020-StocksToWatch.mp3
Read
this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10301SPOR-TRMNF-NMED-MMEDF.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing
yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
In
today’s podcast we look at a few public and private company announcements
focussing specifically on the emerging psychedelic sector.
NEW WAVE HOLDINGS CORP. (CSE: SPOR) (OTC:TRMNF) an investment issuer that provides
capital and support services, announced it will bring Microdose
to Vancouver November 1st - 10th to start production for the next phase of
"The World on Drugs" documentary.
The team
at New Wave is pleased to announce that Microdose is traveling to Vancouver
from November 1-10th, to film the next phase of the upcoming documentary
"The World on Drugs". The production aims to illuminate a bold
commentary on drug policy, psychedelic medicine and mental health comes at a
pivotal moment in our collective evolution. The sharp increase in
opioid-related overdose deaths in B.C. highlight the urgent need for new
treatments and policy, providing the unique opportunity to spotlight
psychedelic medicine. We have scheduled interviews with leading experts in
their respective fields, and would love to hear your suggestions for interview
candidates, key locations, or critical subject matter that should be filmed in
Vancouver, please fill out this open feedback/application form.
"We
would like to thank New Wave Holdings for being our inaugural sponsor for this
next phase of our international effort to document the intersection of mental
health, psychedelic medicine and global drug policy around the world. We are
committed to building a compelling, objective narrative by listening to the
experts, this documentary will truly be a team effort." Microdose CEO -
Patrick Moher
Pilot
footage for "The World on Drugs" was captured in
Mexico where the Microdose team met with notable thought leaders, clinicians
and psychedelic medicine providers. For any general partnership inquiries,
please reach out to Connor Haslem at: Connor@microdose.buzz.
"The
Microdose team hopes to continue the journey by heading to Portugal, where full
drug decriminalization provides fascinating insight into a potential, more
progressive way forward. We also intend on going to Jamaica, another iconic
location significantly impacted by the War on Drugs that is pioneering new
mental health treatments. As our worldwide documentary filmmaking journey
progresses, we hope to illuminate the potential of psychedelic medicine to
disrupt the mental health crisis across the globe." - Patrick Moher
continued.
The data
form: If you or anyone you know wants to contribute or is interested to
collaborate on this project, please fill out this form. We do have a limited
filming period that is available, so unfortunately we won't be able to connect
directly with all submissions-but, everybody that fills this form out on behalf
of somebody or behalf of themselves will get a free copy of the completed film
as a thank you gift for your contribution.
If you
are interested in getting involved with this dynamic documentary filmmaking
project in terms of collaboration, sponsorship or general input, please reach
out to Connor Haslem at: Connor@microdose.buzz
MagicMed
Industries Inc. announced that it has entered into a Research
Contract and a Facilities Use Agreement with the University of Calgary. The Agreements provide MagicMed with further
scientific and laboratory support to accelerate development of its psychedelic
derivatives patent library, the PsybraryTM.
"The
University of Calgary is excited to partner with MagicMed, an innovative
company pursuing psychedelics research," says Associate Vice-President
(Research – Innovation), Dr. Steve Larter. "Partnerships like this combine
frontline discovery with providing real solutions to society and create
opportunities for our researchers and students to help bring cutting-edge
knowledge to market."
"The
additional resources that the University of Calgary is providing to MagicMed
compliment and enhance our strengths," says Dr. Joseph Tucker, CEO
MagicMed. "This collaboration places MagicMed in a position to expand the
breadth and depth of the psychedelic derivatives contained in the MagicMed
PsybraryTM."
Through
the Agreements, MagicMed will be able to leverage new state of the art
equipment and laboratory space at the University of Calgary, as well as draw
upon its world-class expertise. Laboratory
and resource costs of the MagicMed PsybraryTM expansion will be efficiently allocated while development progress
will be expedited.
Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced that it has closed its previously
announced bought deal short form prospectus offering, including the exercise in
full of the underwriter's over-allotment option. In connection with the
Offering, the Company issued 27,381,500 units of the Company at a price per
Unit of $1.05 for gross proceeds of $28,750,575. Canaccord Genuity Corp. acted
as sole bookrunner and underwriter in the Offering.
Each
Unit comprises one subordinate voting share of the Company and one-half of one
Subordinate Voting Share purchase warrant. Each Warrant entitles the holder
thereof to purchase one Subordinate Voting Share at an exercise price of $1.40
until October 30, 2023. The Warrants will be listed for trading on the
facilities of the NEO Exchange Inc. under the symbol "MMED.WS",
subject to the final approval of the NEO.
MindMed
Co-Founder & Co-CEO, J.R. Rahn said "The strong institutional investor
interest for this oversubscribed financing demonstrates the vast appetite for
companies pursuing clinical trials of psychedelic medicines with the FDA and
other regulatory bodies. With our sights set on a NASDAQ up-listing, this fresh
funding will further assist the MindMed team in our mission to build the most
diverse development pipeline of psychedelic inspired medicines and experiential
therapies for patients."
Post-financing
the Company now has cash reserves of CAD $50.1m (USD $37.8m) to enable
continued progress of its clinical trial pipeline of psychedelic inspired
medicines and experiential therapies.
The Company
intends to use the net proceeds of the Offering for investment in its research
and clinical development initiatives, including its 18-MC addiction treatment
program derived from the psychedelic ibogaine, lysergic acid diethylamide (LSD)
microdose program for Adult ADHD, Project Lucy focused on LSD experiential
therapy for anxiety disorders, University Hospital Basel Liechti Lab research
and development collaboration, its partnership with NYU Langone Health for a
Psychedelic Medicine Research Training Program, and for general working capital
and corporate development purposes.
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy nor shall there be any sale of the securities in any state in
which such offer, solicitation or sale would be unlawful. The securities being
offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and
applicable state securities laws.
MindMed
is a psychedelic medicine biotech company that discovers, develops and deploys
psychedelic inspired medicines and experiential therapies to address addiction
and mental illness. The Company is assembling a compelling drug development
pipeline of innovative treatments based on psychedelic substances including
Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed team
brings extensive biopharmaceutical experience to the Company's groundbreaking
approach to developing the next generation of psychedelic inspired medicines
and experiential therapies.
In
closing today’s podcast if you are still on the fence about the benefits of
psychedelic medicine (or cannabis) we’ve included two book recommendations that
do an amazing job of illustrating the importance and necessity of whole plant
based medicines in the modern world, especially in a COVID world.
The
first is “Psychedelic Medicine: The
Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca” which explores the
potential of psychedelics as medicine and the intersections of politics,
science, and psychedelics as well as offers non-technical summaries of the most
recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD,
and ayahuasca. This book includes the work of Rick Doblin, Stanislav Grof,
James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil
Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and
Robert Whitaker and is available on Amazon or if you’re in Canada, you can buy
online from my local head shop Mary Jane’s HQ.
The
second has garnered more controversy but is, in my opinion, a must read during
this time in history particularly, is “Thus
Spoke the Plant: A Remarkable Journey of Groundbreaking Scientific Discoveries
and Personal Encounters with Plants” by Monica Gagliano. This book is both haunting and profound and
offers a new perspective on plants, medicine and communication with nature in
the modern world. This book is also available on Amazon and you listen to her in depth
discussion on plant consciousness on Youtube
to hear her words directly.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors
can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on
Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about
publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
No comments:
Post a Comment